Literature DB >> 21749363

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

Ethan B Russo1.   

Abstract

Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene, exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study. This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol and phytol. Terpenoids share a precursor with phytocannabinoids, and are all flavour and fragrance components common to human diets that have been designated Generally Recognized as Safe by the US Food and Drug Administration and other regulatory agencies. Terpenoids are quite potent, and affect animal and even human behaviour when inhaled from ambient air at serum levels in the single digits ng·mL(-1) . They display unique therapeutic effects that may contribute meaningfully to the entourage effects of cannabis-based medicinal extracts. Particular focus will be placed on phytocannabinoid-terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin-resistant Staphylococcus aureus). Scientific evidence is presented for non-cannabinoid plant components as putative antidotes to intoxicating effects of THC that could increase its therapeutic index. Methods for investigating entourage effects in future experiments will be proposed. Phytocannabinoid-terpenoid synergy, if proven, increases the likelihood that an extensive pipeline of new therapeutic products is possible from this venerable plant. http://dx.doi.org/10.1111/bph.2011.163.issue-7.
© 2011 The Author. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21749363      PMCID: PMC3165946          DOI: 10.1111/j.1476-5381.2011.01238.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  218 in total

1.  Local anaesthetic activity of the essential oil of Lavandula angustifolia.

Authors:  C Ghelardini; N Galeotti; G Salvatore; G Mazzanti
Journal:  Planta Med       Date:  1999-12       Impact factor: 3.352

Review 2.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

3.  In vitro inhibition of CYP2B1 monooxygenase by beta-myrcene and other monoterpenoid compounds.

Authors:  A C De-Oliveira; L F Ribeiro-Pinto; J R Paumgartten
Journal:  Toxicol Lett       Date:  1997-06-16       Impact factor: 4.372

4.  Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats.

Authors:  Linda A Parker; Raphael Mechoulam; Coralynne Schlievert
Journal:  Neuroreport       Date:  2002-04-16       Impact factor: 1.837

5.  Inhibition of acetylcholinesterase activity by bicyclic monoterpenoids.

Authors:  Mitsuo Miyazawa; Chikako Yamafuji
Journal:  J Agric Food Chem       Date:  2005-03-09       Impact factor: 5.279

6.  Composition and enantiomeric analysis of the essential oil of the fruits and the leaves of Pistacia vera from Greece.

Authors:  Anastasia Tsokou; Katerina Georgopoulou; Eleni Melliou; Prokopios Magiatis; Eugenia Tsitsa
Journal:  Molecules       Date:  2007-06-30       Impact factor: 4.411

7.  Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol.

Authors:  Paolo Fusar-Poli; Paul Allen; Sagnik Bhattacharyya; José A Crippa; Andrea Mechelli; Stefan Borgwardt; Rocio Martin-Santos; Marc L Seal; Colin O'Carrol; Zerrin Atakan; Antonio W Zuardi; Philip McGuire
Journal:  Int J Neuropsychopharmacol       Date:  2009-09-24       Impact factor: 5.176

8.  Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

Authors:  Paolo Fusar-Poli; José A Crippa; Sagnik Bhattacharyya; Stefan J Borgwardt; Paul Allen; Rocio Martin-Santos; Marc Seal; Simon A Surguladze; Colin O'Carrol; Zerrin Atakan; Antonio W Zuardi; Philip K McGuire
Journal:  Arch Gen Psychiatry       Date:  2009-01

9.  Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.

Authors:  Guy W Neff; Christopher B O'Brien; K Rajender Reddy; Nora V Bergasa; Arie Regev; Enrique Molina; Rafael Amaro; Miguel J Rodriguez; VeEtta Chase; Lennox Jeffers; Eugene Schiff
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

10.  Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects?

Authors:  J D Wilkinson; B J Whalley; D Baker; G Pryce; A Constanti; S Gibbons; E M Williamson
Journal:  J Pharm Pharmacol       Date:  2003-12       Impact factor: 3.765

View more
  307 in total

1.  Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice.

Authors:  Angelo A Izzo; Raffaele Capasso; Gabriella Aviello; Francesca Borrelli; Barbara Romano; Fabiana Piscitelli; Laura Gallo; Francesco Capasso; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Perspective: Close the knowledge gap.

Authors:  Jonathan Page; Mark Ware
Journal:  Nature       Date:  2015-09-24       Impact factor: 49.962

3.  Drug development: The treasure chest.

Authors:  Brian Owens
Journal:  Nature       Date:  2015-09-24       Impact factor: 49.962

Review 4.  Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Richard S Bedlack; Nanette Joyce; Gregory T Carter; Sabrina Paganoni; Chafic Karam
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

5.  Gene Networks Underlying Cannabinoid and Terpenoid Accumulation in Cannabis.

Authors:  Jordan J Zager; Iris Lange; Narayanan Srividya; Anthony Smith; B Markus Lange
Journal:  Plant Physiol       Date:  2019-05-28       Impact factor: 8.340

6.  Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

Authors:  Luciano De Petrocellis; Alessia Ligresti; Aniello Schiano Moriello; Mariagrazia Iappelli; Roberta Verde; Colin G Stott; Luigia Cristino; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

7.  Affinity and Efficacy Studies of Tetrahydrocannabinolic Acid A at Cannabinoid Receptor Types One and Two.

Authors:  John M McPartland; Christa MacDonald; Michelle Young; Phillip S Grant; Daniel P Furkert; Michelle Glass
Journal:  Cannabis Cannabinoid Res       Date:  2017-05-01

8.  Impact of Cannabis Use on the Development of Psychotic Disorders.

Authors:  Samuel T Wilkinson; Rajiv Radhakrishnan; Deepak Cyril D'Souza
Journal:  Curr Addict Rep       Date:  2014-06-01

Review 9.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

10.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.